Kemp Proteins, a leading CDMO specializing in the production and characterization of novel proteins, from mammalian, insect, and bacterial host cells, for the pharmaceutical, diagnostics, and research industries, announced today that it has secured financing from BroadOak Capital Partners, LLC (“BroadOak”). The transaction with BroadOak provides Kemp Proteins with capital to expand its bacteria expression and plasmid production services in Frederick, MD.
Kemp Proteins, a leading provider of gene-to-protein and monoclonal antibody development services to the pharmaceutical, diagnostics, and research industries, announced today that it has received ISO 13485:2016 certification for its Quality Management System (QMS). Achieving ISO 9001:2015 (certified since 2020) and now ISO 13485 certification demonstrates Kemp’s commitment to a company culture of continuous improvement and risk-based decision making, focused on providing our client partners with world-class protein development and manufacturing services.
Kemp Proteins, a leading provider of gene-to-protein and monoclonal antibody development services, announced today that the company has appointed Carter Michell, Ph.D. as its new Chief Scientific Officer (CSO). Carter will lead the scientific and technological development of Kemp Proteins as the company continues its impressive growth following its purchase by Six02 Bioservices in January 2019.
In Conversation: CEO Michael Keefe and COO David Hicks of Kemp Proteins April 28, 2020 Kemp Proteins, headquartered in Frederick, Maryland is a gene-to-protein bioservices organization that works as an [….]